NEW YORK (GenomeWeb News) – EMD Millipore today announced a clinical research, licensing, and joint development deal with Japan's Sysmex aimed at creating a flow cytometry platform for blood disorders.

The companies will use EMD Millipore's flow cytometry technology as a platform to accelerate the development of new diagnostic tools. If successful, they will then develop the platform for commercialization in the hematology space, EMD Millipore, division of Germany's Merck KGaA, said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.